As Executive Vice President and Chief Business Officer, Jay Mohr provides business development leadership to the organization and is also responsible for directing NYBC’s cell manufacturing business unit, Comprehensive Cell Solutions®, and for co-managing the Enterprise’s recently-launched investment fund, NYBC Ventures. Jay brings over 30 years of successful executive leadership in the biopharmaceutical industry. Before joining NYBC, Jay served as the Chief Operating and Business Officer of AZTherapies, a privately held biopharma company focused on neurodegenerative diseases. At AZTherapies, Jay implemented financing and business development initiatives, developed and executed corporate strategy, and managed investor relations. Having previously served as CEO of several pharma and life science companies, Jay has vast experience in capital formation, P&L management, and corporate and business development, and in those roles his efforts generated significant shareholder value. He co-founded Dirigo Therapeutics, Locust Walk Partners, and Gloucester Pharmaceuticals. Jay currently serves on the boards of Mesentech, Inc., the T1D Exchange, and the Maine Technological Institute. He currently holds Series 79, 24 and 63 securities licenses. Jay graduated from Vanderbilt University with a Bachelor of Arts in Economics and German. He received his Master of Business Administration from The Wharton School of the University of Pennsylvania.